Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Enliven Advances ENABLE-2 Phase 3; Cash Runway Extends to 2030

Nov 5, 2026, 4:17 PM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

FDA-aligned pivotal trial design reduces execution risk; large cash runway de-risks financing concerns; Phase 3 around 450 patients suggests meaningful data flow and potential for accelerated approval if Week 24 MMR is favorable.

AI summary

What happened, with direct paths to the underlying reporting

Enliven disclosed FDA alignment for the ENABLE-2 pivotal trial of relcobatinib, with initiation expected by year-end 2026. The company holds $884.4 million in cash and equivalents, supporting operations into 2030 and a planned Phase 3 in CML with about 450 patients. Positive data diffusion and upcoming investor events could lift sentiment and valuations for ELVN.

FDA alignment on ENABLE-2 trial design; initiation targeted by year-end 2026.
ENABLE-2 to enroll ~450 patients; primary endpoint is MMR at Week 24.
USAN named relcobatinib ELVN-001; relcobatinib targets BCR::ABL1 in CML.
Company cash $884.4M as of 9/30/2026; runway into 2030.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.